Franklin Covey reaffirms FY2026 guidance of $265M-$275M revenue and $28M-$33M adjusted EBITDA as multiyear mix reaches 62% (NYSE:FC)April 2, 2026
Share Facebook Twitter LinkedIn Pinterest Email Pfizer, Valneva complete recruitment for Phase 3 Lyme vaccine study
Franklin Covey reaffirms FY2026 guidance of $265M-$275M revenue and $28M-$33M adjusted EBITDA as multiyear mix reaches 62% (NYSE:FC)April 2, 2026
